Cargando…

Vancomycin-Loaded Nanoparticles Enhance Sporicidal and Antibacterial Efficacy for Clostridium difficile Infection

Current antibiotic treatments fail to eliminate the Clostridium difficile (C. difficile) spores and induce dysbiosis and intestinal inflammation via off-target effect, which causes refractory C. difficile infection raise an unmet need for a spore-specific antimicrobial treatment. We developed a spor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yi-Hsuan, Li, Tsung-Ju, Tsai, Bo-Yang, Chen, Liang-Kuei, Lai, Yi-Hsin, Li, Meng-Jia, Tsai, Cheng-Yang, Tsai, Pei-Jane, Shieh, Dar-Bin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Microbiology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543869/ https://www.ncbi.nlm.nih.gov/pubmed/31178844 http://dx.doi.org/10.3389/fmicb.2019.01141

Ejemplares similares

Novel metal peroxide nanoboxes restrain Clostridioides difficile infection beyond the bactericidal and sporicidal activity
por: Yang, Li‐Xing, et al.
Publicado: (2023)

Octahedron Iron Oxide Nanocrystals Prohibited Clostridium difficile Spore Germination and Attenuated Local and Systemic Inflammation
por: Lee, Wei-Ting, et al.
Publicado: (2017)

Unlocking the Sporicidal Potential of Ethanol: Induced Sporicidal Activity of Ethanol against Clostridium difficile and Bacillus Spores under Altered Physical and Chemical Conditions
por: Nerandzic, Michelle M., et al.
Publicado: (2015)

Induced Sporicidal Activity of Chlorhexidine against Clostridium difficile Spores under Altered Physical and Chemical Conditions
por: Nerandzic, Michelle M., et al.
Publicado: (2015)

The ATP-P2X(7) Signaling Axis Is an Essential Sentinel for Intracellular Clostridium difficile Pathogen-Induced Inflammasome Activation
por: Liu, Ya-Hui, et al.
Publicado: (2018)

Corrigendum: The ATP-P2X(7) Signaling Axis Is an Essential Sentinel for Intracellular Clostridium difficile Pathogen-Induced Inflammasome Activation
por: Liu, Ya-Hui, et al.
Publicado: (2019)

Membrane Cholesterol Is Crucial for Clostridium difficile Surface Layer Protein Binding and Triggering Inflammasome Activation
por: Chen, Yu, et al.
Publicado: (2020)

Antibacterial and Sporicidal Activity Evaluation of Theaflavin-3,3′-digallate
por: Yussof, Ayuni, et al.
Publicado: (2022)

Evaluating the Sporicidal Activity of Disinfectants against Clostridium difficile and Bacillus amyloliquefaciens Spores by Using the Improved Methods Based on ASTM E2197-11
por: Uwamahoro, Marie Christine, et al.
Publicado: (2018)

The Transcriptional Regulator Lrp Contributes to Toxin Expression, Sporulation, and Swimming Motility in Clostridium difficile
por: Chen, Kuan-Yu, et al.
Publicado: (2019)

Effect of Doxycycline in Decreasing the Severity of Clostridioides difficile Infection in Mice
por: Tsai, Bo-Yang, et al.
Publicado: (2022)

Gold Nanoclusters as an Antibacterial Alternative Against Clostridium difficile
por: Yang, Huan, et al.
Publicado: (2020)

Immunization with Recombinant TcdB-Encapsulated Nanocomplex Induces Protection against Clostridium difficile Challenge in a Mouse Model
por: Liu, Yi-Wen, et al.
Publicado: (2017)

Vancomycin Enemas as Adjunctive Therapy for Clostridium difficile Infection
por: Malamood, Mark, et al.
Publicado: (2015)

Comparison of Fidaxomicin and Vancomycin for Recurrent Clostridium difficile Colitis
por: Khoo, Teresa, et al.
Publicado: (2017)

Predominance of Clostridium difficile Ribotypes 017 and 078 among Toxigenic Clinical Isolates in Southern Taiwan
por: Hung, Yuan-Pin, et al.
Publicado: (2016)

Impact of Toxigenic Clostridium difficile Colonization and Infection among Hospitalized Adults at a District Hospital in Southern Taiwan
por: Hung, Yuan-Pin, et al.
Publicado: (2012)

Oral vancomycin desensitisation to treat Clostridium difficile infection in a vancomycin allergic patient
por: Mahabir, Shanti, et al.
Publicado: (2013)

A Cumulative Spore Killing Approach: Synergistic Sporicidal Activity of Dilute Peracetic Acid and Ethanol at Low pH Against Clostridium difficile and Bacillus subtilis Spores
por: Nerandzic, Michelle M., et al.
Publicado: (2015)

Enhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
por: Thorpe, Cheleste M., et al.
Publicado: (2018)

Proteomic Signatures of Clostridium difficile Stressed with Metronidazole, Vancomycin, or Fidaxomicin
por: Maaß, Sandra, et al.
Publicado: (2018)

Economic Barriers in the Treatment of Clostridium difficile Infection With Oral Vancomycin
por: Bunnell, Kristen L., et al.
Publicado: (2017)

Concomitant Vancomycin-Resistant Enterococcus faecium and Clostridium difficile Colitis
por: Mehershahi, Shehriyar, et al.
Publicado: (2021)

Piperacillin/tazobactam/vancomycin: Clostridium difficile colitis: case report
Publicado: (2021)

1980. Efficacy of an Oral Vancomycin Loading Dose (LD) in the Treatment of Confirmed Clostridium Difficile Infection (CDI)
por: Tirmizi, Samad, et al.
Publicado: (2018)

Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection
por: Hung, Yuan-Pin, et al.
Publicado: (2015)

Sporicidal Action of Pulsed Radiation of Hot Plasma
por: Piskarev, I.M., et al.
Publicado: (2022)

Antibacterial effect of Manuka honey on Clostridium difficile
por: Hammond, Eric N, et al.
Publicado: (2013)

Treatment of Clostridium difficile infection in mice with vancomycin alone is as effective as treatment with vancomycin and metronidazole in combination
por: Erikstrup, Lise Tornvig, et al.
Publicado: (2015)

Initial Oral Vancomycin vs. Oral Vancomycin After Metronidazole for Severe Clostridium difficile Infection
por: Shah, Sunish, et al.
Publicado: (2017)

Risk factors and outcomes of Clostridium difficile infection in hospitalized patients
por: Lee, Hao-Yuan, et al.
Publicado: (2019)

Refractory Clostridium difficile Infection Successfully Treated with Tigecycline, Rifaximin, and Vancomycin
por: Lao, Dominador, et al.
Publicado: (2012)

Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections
por: Weiss, Karl, et al.
Publicado: (2012)

Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin
por: Cornely, Oliver A., et al.
Publicado: (2012)

Therapeutic Success of Rifaximin for Clostridium difficile Infection Refractory to Metronidazole and Vancomycin
por: Tannous, George, et al.
Publicado: (2010)

Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection
por: Nathwani, Dilip, et al.
Publicado: (2014)

Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection
por: Zhang, Kevin, et al.
Publicado: (2019)

Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes
por: Lee, Christine, et al.
Publicado: (2016)

The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients
por: Lai, Yi-Hsin, et al.
Publicado: (2021)

Corrigendum: The Role of Toll-Like Receptor-2 in Clostridioides difficile Infection: Evidence From a Mouse Model and Clinical Patients
por: Lai, Yi-Hsin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k9omslnolvurqla4t1eejp08m6